You've seen the pitch: polyphenols "switch on Nrf2," your body's master antioxidant regulator, and your cells supposedly become more resilient. A new systematic review and meta-analysis in Nutrition and Health tested that story in humans. The results are messier than the supplement aisle suggests, and one of biohacking's favorite molecules, resveratrol, came out looking like the odd one out.
The headline finding: resveratrol went the wrong way
The researchers, from the Universidad Autónoma de Chihuahua, pooled nine human trials covering 552 participants (376 men, 176 women). The trials were randomized controlled or pre-experimental studies that compared polyphenol supplementation with placebo and measured Nrf2 activation.
The overall result is the first thing to know: polyphenol supplementation as a group did not significantly change Nrf2 expression in humans. The blanket claim that polyphenols reliably activate Nrf2, which holds up reasonably well in animal models, did not hold up here.
The compound-by-compound breakdown is where it gets interesting. Resveratrol supplementation was associated with significantly lower Nrf2 activation (p = 0.03). That is not what most longevity enthusiasts expect from a headline "pathway activator." It is a statistical signal from a small pool of studies, not proof that resveratrol harms your antioxidant defenses. It does suggest the animal-to-human leap is not guaranteed.
The winner: isoflavones
Isoflavones, the soy-associated polyphenols, showed the most pronounced upregulation of Nrf2 (p < 0.00001). The combination of chlorogenic acid and N-methylpyridinium, compounds associated with coffee, came next (p = 0.0008).
Treat these as leads, not verdicts. The authors stress that the favorable effects appeared in individual studies, and that the evidence base is small and carries a risk of bias. A very small p-value from a handful of trials is not the same as a robust, replicated effect.
The no-shows: curcumin, sulforaphane, bilberry
Three popular candidates did not show statistically significant differences in Nrf2 activation:
- Curcumin
- Sulforaphane
- Bilberry pomace extract
This does not mean these compounds do nothing. It means that in the trials analyzed, with the Nrf2 measures used, no clear signal emerged. Sulforaphane in particular is famous in preclinical work as an Nrf2 inducer, so a null result here highlights how much the outcome depends on dose, formulation, tissue sampled, and how Nrf2 is measured.
Why the human data are so slippery
Several caveats matter before you rebuild a stack around this paper:
- Only nine studies. Splitting them by compound leaves very few trials per polyphenol.
- Risk of bias. The authors flag methodological limitations in the included trials.
- Mixed designs. Including pre-experimental trials weakens causal inference compared with pure randomized trials.
- Measurement matters. Nrf2 "expression" in blood cells may not reflect what happens in liver, muscle, or brain tissue.
- Nrf2 activity is not the same as health outcomes. The review looked at the pathway marker, not lifespan, disease, or performance.
The evidence here is human, but it is a small, low-certainty synthesis. It cannot show that any compound extends life or improves health.
Practical takeaways: dose, timing, who it's for
Dose and timing: The abstract does not report specific doses, durations, or timing protocols, and the pooled analysis cannot support a recommended regimen. Anyone claiming a "proven Nrf2 dose" from this paper is overreaching. If you use any of these compounds, follow the product's labeling or your clinician's guidance rather than this study.
Who might care:
- Resveratrol users: Don't panic, but don't assume it is an Nrf2 booster. If your goal is specifically to support this pathway, the human evidence is weaker than the marketing implies. Resveratrol may have other effects, but this review does not address them.
- Soy and isoflavone-curious readers: Dietary sources of isoflavones, such as soy foods, are a low-risk area to watch. This review does not prove that they raise Nrf2 in a meaningful way, and isoflavone supplements have their own considerations. People with hormone-sensitive conditions or thyroid issues should talk to a clinician first.
- Coffee drinkers: The chlorogenic acid plus N-methylpyridinium signal is intriguing, but it does not justify changing your caffeine habits on its own.
- Curcumin and sulforaphane fans: The null results say "unproven for Nrf2 in humans," not "useless."
The smart play: Treat Nrf2 as a hypothesis, not a dial you can reliably turn with a capsule. If you track biomarkers, compare changes over time rather than trusting a pathway story.
The bottom line
The most striking result is not a miracle compound but a reality check. Across human trials, polyphenols as a class did not significantly move Nrf2, resveratrol appeared to push it down, and isoflavones plus coffee-related compounds showed promise that still needs confirmation. The authors call for methodologically sound clinical trials, and until those arrive, the Nrf2-activating supplement narrative remains stronger in animal models than in people.